HORSHAM, Pa.--(BUSINESS WIRE)--Neose Technologies, Inc. (NasdaqGM:NTEC) today announced that it received a milestone payment from Novo Nordisk A/S (NYSE:NVO) under a license agreement entered into November 2003 for the use of Neose’s GlycoPEGylation™ technology to develop a next-generation version of Factor VIIa. The Company is also working with Novo Nordisk to develop next-generation versions of Factors VIII and IX.
